Organon & Co. (ogn)

OGN — Company Overview

Organon & Co. (OGN) trades on NYQ as part of the Healthcare peer group (Drug Manufacturers - General).

OGN — Business Description

OGN represents a Drug Manufacturers - General business in the Healthcare segment. Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorr…

Official website: https://www.organon.com.

OGN — Investment Thesis

At a high level, OGN offers exposure to Healthcare with metrics outlined below from public market data.

• Revenue is contracting at roughly -2.3% year-over-year (public data).
• Trailing P/E of 17.60× sits in a moderate band relative to high-growth peers.
• Forward P/E (3.80×) is below trailing P/E — earnings may be expected to improve.
• Dividend yield near 0.6% adds an income component to total return.
• Equity market capitalization is approximately $3.61B.

See the free estimates and earnings pages for public targets and growth metrics. Ownership, live news, and deeper models remain in Vest Terminal.

OGN — Financial Health

Key financial health indicators for Organon & Co. are derived exclusively from public data — no proprietary estimates.

Profit margin near 3.4% leaves a narrower cushion versus higher-margin peers. Positive free cash flow of $490.75M supports balance-sheet flexibility. Debt-to-equity of 850.20 warrants monitoring in a higher-rate environment.

OGN — Growth Outlook

Growth outlook for Organon & Co. (OGN) depends on demand trends in Drug Manufacturers - General and the company's ability to convert revenue into sustainable earnings.

• Revenue decline of -2.3% highlights near-term demand headwinds.
• Earnings declined -28.3% year-over-year — margin or volume pressure may be in play.
• Price is 0.4% below the 52-week high.

OGN — Competitive Position

Organon & Co. (OGN) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.

• Competes within Healthcare, specifically in Drug Manufacturers - General.
• Market capitalization of $3.61B places OGN among mid-cap peers.
• Gross margin near 53.4% may reflect pricing power or favorable mix.

OGN — Summary

Organon & Co. (OGN) is a mid-cap Healthcare company focused on Drug Manufacturers - General, listed on NYQ. Last price $13.73 with market cap $3.61B. Trailing P/E 17.60×. Revenue declined -2.3% year-over-year per public data. Notable strengths include return on equity near 24.0% — efficient use of shareholder capital. Key watch items include revenue contraction of -2.3% year-over-year. Premium Terminal tools for Organon & Co. add ownership analytics, news, and richer estimate history beyond this public summary.